TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05649137
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive once-weekly s.c. injection of placebo matched to semaglutide for 72 weeks. Injections may be administered in the thigh, abdomen, or upper arm, at any time of day irrespective of meals.
Study: NCT06351592
Drug: Placebo (PB)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered by IT injection
Study: NCT05278104
Drug: Zentiva®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zentiva®
Study: NCT05278104
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT06021457
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration
Study: NCT06131372
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive placebo matched to cagrilintide or placebo matched to semaglutide subcutaneously.
Study: NCT06164704
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verekitug (UPB-101) matching placebo
Study: NCT06243575
Drug: Multimodal Intraosseous Femoral Injection
Normalized name: Sus scrofa temporal lobe preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraosseous injection of Ketorolac 15mg and Tranexamic acid 500mg in femoral canal
Study: NCT06243575
Drug: Multimodal Intraosseous Tibial Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraosseous injection of Ketorolac 15mg and Tranexamic acid 500mg in tibial canal
Study: NCT06360133
Drug: VVN001 Ophthalmic Solution, 5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: VVN001 Ophthalmic Solution, 5%
Study: NCT06360133
Drug: VVN001 Ophthalmic Solution, Vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: VVN001 Ophthalmic Solution, Vehicle
Study: NCT06292689
Drug: Cardunolizumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1. Not systematically treated:~   Cardunolizumab (10mg/kg) + Cisplatinum (50mg/m2)/ Carboplatinum (AUC 4-5) + Paclitaxel (175mg/m2) ± Bevacizumab (15mg/kg) for 6 cycles, every 3 weeks (Q3W), and then Cardunolizumab ± Bevacizumab Q3W maintenance treatment.~2. Previous systematic treatment:~Cardunolizumab (10mg/kg) + Chemotherapy regimen selected by the investigator ± Bevacizumab (15mg/kg) for 6 cycles, every 3 weeks (Q3W), and then Cardunolizumab ± Bevacizumab Q3W maintenance treatment.
Study: NCT01894308
Drug: Testosterone
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10,30,50 and 70 mg doses of micronized Testosterone delivered by means of a new liquid transdermal delivery solution, HypoSpray(R)once daily for 7 days or until halted due to systemic or dermal reactions.
Study: NCT04826822
Drug: Spironolactone + Dexamethasone
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Low doses of orally administered spironolactone and dexamethasone
Study: NCT04826822
Drug: Standard-of-care SARS-CoV-2 treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-of-care SARS-CoV-2 treatment administered according to the local guidelines
Study: NCT05521386
Drug: Caffeine
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single pill in an acute dose of 5 mg per kg of body mass
Study: NCT05521386
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single pill in an acute dose of 5 mg per kg of body mass
Study: NCT05335928
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: Standard of care Local standard of care per written policies or guidelines Other Name: SoC
Study: NCT05920642
Drug: Parenteral administration of analgesics
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard postoperative pain management of analgesics using parenteral route of administration.
Study: NCT06433713
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% normal saline infusion
Study: NCT06515678
Drug: arm A - angiotensin converting enzyme inhibitors (ACEi)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with ACEi monotherapy before or within 6 months following debulking surgery.~ACEi will be defined as any drugs from the Anatomical Therapeutic Classification C09AA with an indication for hypertension, including but not limited to: captopril, enalapril, lisinopril, perindopril, ramipril, quinapril
Study: NCT06515678
Drug: arm B - calcium channel blockers (CCBs)
Normalized name: Channel catfish
DrugBank: Channel catfish (DB15548)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with CCB monotherapy before or within 6 months following debulking surgery.~CCBs will be defined as any drugs from the Anatomical Therapeutic Classification C08CA with an indication for hypertension, including but not limited to: amlodipine, felodipine, isradipine, nicardipine, nifedipine
Study: NCT05403476
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo is administered as single daily subcutaneous injection dialed to the same value (dose) as FE 999049 for 6 months.
Study: NCT05587699
Drug: CKD-843-R
Normalized name: R
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5mg/day, 9 Month
Study: NCT05585346
Drug: Oral vitamin B1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral vitamin B1 10mg, times/day
Study: NCT05361733
Drug: XFB-19
Approvals — FDA: no, EMA: no, PMDA: no
Description: XFB-19 is a first-in-class synthetic tetra-peptide (Acetyl-Lys-D-Ala-D-Val-Asp-NH2) that inhibits the activation of the human CCAAT-enhancer binding protein beta (C/EBPβ) thus mediating the activation of lung myofibroblasts. Activation of myofibroblasts is responsible for the development of lung fibrosis in idiopathic pulmonary fibrosis (IPF).
Study: NCT05361733
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: No active ingredient drug use to blind participants and investigators
Study: NCT04551066
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo will be administered QD orally
Study: NCT05628883
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants will receive Cyclophosphamide 60 mg/kg/day intravenously (IV) in 250 mL over approximately 1 hour per day for 2 days.
Study: NCT05900895
Drug: 17b-estradiol
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 17b-estradiol will be taken orally three times per day.
Study: NCT06371664
Drug: Conventional Tray (1 mm)
Approvals — FDA: no, EMA: no, PMDA: no
Description: General examination with bite-wings. Dental prophylaxis (dental scaling and polishing with an abrasive paste). Alginate impressions of both arches. Creation of conventional individualized bleaching trays (trimmed 1 mm above the gingival margin) and a position-finder tray of both arches. Application of the bleaching gel in the bleaching trays during 6-8 hours
Study: NCT06371664
Drug: Extended Tray (3 mm)
Approvals — FDA: no, EMA: no, PMDA: no
Description: General examination with bite-wings. Dental prophylaxis (dental scaling and polishing with an abrasive paste). Alginate impressions of both arches. Creation of extended individualized bleaching trays (trimmed 3 mm above the gingival margin) and a position-finder tray of both arches. Application of the bleaching gel in the bleaching trays during 6-8 hours
Study: NCT06379867
Drug: HSK3486
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 mg/kg, IV bolus administration
Study: NCT06379867
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV bolus administration
Study: NCT05823168
Drug: Antiepileptic Drug
Normalized name: ANTIEPILEPTICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: we osberve the efficacy of antiepileptic drungs on preventing seizures and their impact on rehabilitation outcome
Study: NCT04658472
Drug: SAR445088 (IV)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: Solution for Injection Route of Administration: Intravenous (IV)
Study: NCT04658472
Drug: SAR445088 (SC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: Solution for Injection Route of Administration: Subcutaneous (SC)
Study: NCT04417114
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Statin
Study: NCT06299579
Drug: GD-11 for injection test group
Approvals — FDA: no, EMA: no, PMDA: no
Description: The first dose of GD-11 was administered as soon as possible after randomization and then every 12±1 hour. A total of 20 doses were required.
Study: NCT06299579
Drug: Placebo control group
Approvals — FDA: no, EMA: no, PMDA: no
Description: The first dose of placebo was administered as soon as possible after randomization and then every 12±1 hour. A total of 20 doses were required.
Study: NCT04556370
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline infusion simultaneous with subarachnoid block
Study: NCT04556370
Drug: Norepinephrine
Normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Different infusion dose of norepinephrine simultaneous with subarachnoid block
Study: NCT04886193
Drug: FLOT(Docetaxel+oxaliplatin+leucovorin+5-FU), Treprizumab, Tiggio capsule (S-1)
Approvals — FDA: no, EMA: no, PMDA: no
Description: * FLOT: Docetaxel 50mg/m2 ivd d1 + oxaliplatin 85mg/m2 ivd d1 + leucovorin 200mg/m2 ivd d1 + 5-FU 2600mg/m2 civ 24h Q2W~* Treprizumab 3mg/kg, intravenously administered on the first day of each cycle, Q2W~* Tiggio capsule (S-1) 40-60mg (BSA\<1.25 m2: 40mg, 1.25 m2≤BSA≤1.5 m2: 50mg, BSA\> 1.5 m2: 60mg) po bid d1-14 Q3W, continuous treatment for 1 year;~* Teriprizumab 240mg, intravenously, given on the first day of each cycle, Q3W, continuous treatment for 1 year.
Study: NCT05896046
Drug: SHR2554+ SHR1701
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR2554: 350mg/day, PO, twice a day. SHR1701: recommended dose from phase I trial, IV, over 30 minutes.
Study: NCT05152277
Drug: HRS9531
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC once
Study: NCT05152277
Drug: HRS9531
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC for multiple dose
Study: NCT04965129
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: Placebo olive oil pill manufactured to mimic fish oil. Other Names: • Placebo
Study: NCT05019755
Drug: IN-A002(IN-115314) capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Administration of IN-A002(IN-115314), single dose
Study: NCT04782804
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine+PD-1 Antibody（Tislelizumab）as Adjuvant Therapy Oral capecitabine (1250 mg/m²) was given post operatively twice a day on days 1 to 14 of a 3-weekly cycle for 24 weeks (eight cycles), and observation commenced within 16 weeks of surgery.
Study: NCT02493322
Drug: Olmesartan Medoxomil 20mg + Chlorthalidone 12,5mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet a day
Study: NCT02493322
Drug: Olmesartan 20mg + hydrochlorothiazide 12,5mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet a day
Study: NCT04861558
Drug: 5Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Injection of 250-850 mg/m2.
Study: NCT05093998
Drug: AV5080
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral hard gelatin capsules
Study: NCT06517862
Drug: Zinc sulfate
Normalized name: Zinc Sulfate
DrugBank: Zinc acetate (DB14487)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Neonates will receive oral Zn sulfate solution in either low doses (10 mg/day) or high doses (20 mg/day) given twice daily.
Study: NCT04849819
Drug: Corticosteroids, immunosuppressors, biological agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: We do not prescribe new medications to patients but only observe their adverse effects on the eye.
Study: NCT04731623
Drug: ION904
Approvals — FDA: no, EMA: no, PMDA: no
Description: ION904 will be administered by SC injection.
Study: NCT04731623
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (0.9% sterile saline) will be administered by SC injection.
Study: NCT05399030
Drug: ICP-332
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICP-332 will be administered as tablet
Study: NCT04715048
Drug: PrabotulinumtoxinA
Normalized name: PrabotulinumtoxinA
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glabellar line correction
Study: NCT05024747
Drug: NicoDerm CQ patch (GSK Dungarvan)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single patch of a NicoDerm CQ (GSK Dungarvan) 21 mg per system of 22 centimeter square (cm\^2) surface area will be placed topically.
Study: NCT05684952
Drug: Shenlingcao Oral Liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shenlingcao oral liquid (200ml/bottle) is comprised of American Ginseng (Panacis Quinquefolii Radix), Lucid Ganoderma (Ganoderma), Rose (Rosae Rugosae Flos) and fermented Cordyceps powder.
Study: NCT06281405
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine: 1000mg/m2 bid d1-14 q3w
Study: NCT02683018
Drug: Smoked Cannabis High CBD/low THC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will visit the Marijuana Research Laboratory 3-5 weekdays per week for 4 weeks to be administered 1-2 cannabis cigarettes (15.76% CBD; 3.11% THC) over the course of a 2-3 hour session.
Study: NCT02683018
Drug: Smoked Placebo Cannabis Low CBD/low THC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will visit the Marijuana Research Laboratory 3-5 weekdays per week for 4 weeks to be administered 1-2 cannabis cigarettes (0.01% THC; 0.00% CBD) over the course of a 2-3 hour session.
Study: NCT04965506
Drug: IBI362
Approvals — FDA: no, EMA: no, PMDA: no
Description: IBI362 administered subcutaneously (SC) once a week.
Study: NCT04430283
Drug: FDY-5301
Approvals — FDA: no, EMA: no, PMDA: no
Description: FDY-5301 is Sodium Iodide administered as an isotonic solution for intravenous injection with a concentration of 7.2 mg/ml.
Study: NCT03734952
Drug: Neoadjuvant chemotherapy Program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy is delivered concomitantly and composed of two cycles of Docetaxel 60mg per square meter of body-surface area and cisplatin 75mg per square meter of body-surface area every 21 days at the intervals of neoadjuvant radiotherapy.
Study: NCT05124977
Drug: Antimicrobial Stewardship
Normalized name: GAUZE,ANTIMICROBIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antimicrobial stewardship based on daily clinical assessment of clinical cure. Discontinuation of appropriate antibiotic therapy antibiotics if criteria of clinical cure of confirmed pneumonia are met. Intensivists will perform clinical assessment daily in order to decide on the pursuit or discontinuation of antibiotic therapy.
Study: NCT05124977
Drug: Standard management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard management: duration of appropriate antibiotic for confirmed pneumonia fixed for 7 days according to guidelines. In the control group, intensivists will perform clinical assessment daily, but the antibiotic will not be discontinued until 7 days whatever the clinical cure.
Study: NCT06121492
Drug: Branched-chain amino acid
Normalized name: Branched-chain amino acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: In the BCAA group, participants will receive oral BCAA for 24 weeks, with a daily dosage of approximately 13.68 g/day. Each sachet of BCAA will contain 6.84 g of BCAA (valine 1.82 g, leucine 3.29 g, isoleucine 1.72 g), total protein 17.08 g, carbohydrates 25.48 g, fat 5.66 g, providing 221.2 kcal of energy. Each sachet weighs 52 g and should be mixed with 150 ml of water. Participants will consume 2 sachets daily, one after breakfast and one after dinner.
Study: NCT05363670
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT04861948
Drug: IBI188
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous
Study: NCT05053126
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participant will receive an oral dose of placebo
Study: NCT06305221
Drug: Opioid-free Analgesics (esketamine, dexmedetomidine)
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: opioid free group: After infusion of a loading dose of dexmedetomidine, intravenous midazolam 2mg, propofol 2mg kg-1, esketamine 0.5 mg kg-1, rocuronium 0.6-1mg kg-1, and 3min after endotracheal intubation. Intravenous continuous infusion of propofol, esketamine and dexmedetomidine hydrochloride mixture (esketamine 50mg + dexmedetomidine hydrochloride 150 ug + 0.9% saline 50ml in the same 50ml syringe) 0.1ml kg-1 h-1-0.2 ml kg-1 h-1 (equivalent to esketamine 0.1-0.2mg kg-1 h-1; Dexmedetomidine hydrochloride 0.3-0.6 μ g kg-1 h-1) maintains a BIS value between 40-60, 10-20mg / time was added as appropriate.
Study: NCT06305221
Drug: Opioid Anesthetics (sufentanil and remifentanil)
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous midazolam 2mg, propofol 2mg kg-1, sufentanyl 0.3-0.5 μ g kg-1, rocuronium 0.6-1mg kg-1,3min before endotracheal intubation. After successful endotracheal intubation, continuous intravenous infusion of propofol and remifentanil was started to maintain BIS values between 40-60, and rocuronium 10-20mg / time as appropriate. After the start of surgery, 10-20 μ g of sufentanil was added according to blood pressure and heart rate. At the end of the operation, 5mg and 50mg were injected before the end of the operation, and propofol and remifentanil were stopped at the end of the operation
Study: NCT05840341
Drug: QingyiHuaji optimized formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qingyihuaji Optimization Formula each bag contains: (1)Scutellaria barbata D. Don (Banzhilian); (2) Hedyotis diffusa Willd. (Sheshecao); (3) Amorphophallus rivieri Durieu (Sheliugu); (4) Amomi Fructus Rotundus (Doukou); (5) Gynostemma pentaphyllum (Thunb.) Makino (Jiaogulan); (6) Semen Coicis (Yiyiren); (7) Ganoderma lucidum (Curtis) P. Karst. (Lingzhi). One bag at a time, twice a day, rinsing with boiling water, continuous administration, oral administration in the morning and evening, every 3 weeks as a cycle.
Study: NCT01017822
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04948463
Drug: Amikacin Injection
Normalized name: amikacin Injection
DrugBank: Amikacin (DB00479)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given until ANC recovery at 18-22.5mg/kg (max 1.5g) daily in combination with other antibiotic/s.
Study: NCT04948463
Drug: Amikacin Injection
Normalized name: amikacin Injection
DrugBank: Amikacin (DB00479)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: At 18-22.5mg/kg (max 1.5g) daily in combination with other antibiotic/s, stopping 48 hours post-fever resolution
Study: NCT06362460
Drug: [14C] RAY1216
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg suspension containing 100μCi of \[14C\]RAY1216
Study: NCT04591210
Drug: Angiotensin converting enzyme inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: The study recommends physicians to select an ACEi with proven benefit in cardiovascular diseases such as perindopril, ramipril or enalapril. Lab values will be obtained during baseline. The patient will be followed by the physician clinically, with recommended laboratory testing in one week, including renal function, potassium assessment, and dose adjustments as appropriate.
Study: NCT04625361
Drug: HEC122505MsOH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part2：Mulltiple doses once daily, up to 8 days
Study: NCT06435182
Drug: OT202 conc 0.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apply 1-2 drops of OT202 0.5% solution into the conjunctival sac. three times daily
Study: NCT06435182
Drug: OT202 conc 0.1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apply 1-2 drops of OT202 0.1% solution into the conjunctival sac. three times daily
Study: NCT06435182
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apply 1-2 drops of placebo solution into the conjunctival sac. three times daily
Study: NCT05603754
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One intra-articular injection of 0 mg lorecivivint in 2 mL vehicle
Study: NCT06499727
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of equally looking placebo capsules in the morning and in the evening, starting 24 hours before departure to 3600 m.
Study: NCT05399550
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching Intravenous Solution
Study: NCT04334915
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT06194981
Drug: Oxaliplatin and capecitabine/ S-1 and capecitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: capecitabine: 1000 mg/m² bid, po, d1-14, oxaliplatin: 130mg/m², iv drip for 2h, d1; S-1: BSA\<1.25m², 40mg bid, 1.25m²≤BSA≤1.5m², 50mg bid, BSA\>1.5m², 60mg bid, po, d1-14, oxaliplatin: 130mg/m², iv drip for 2h, d1
Study: NCT05161637
Drug: TLC590
Approvals — FDA: no, EMA: no, PMDA: no
Description: TLC590 490mg or 588mg
Study: NCT05161637
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline 20mL or 24mL
Study: NCT06141655
Drug: Influenza vaccine
Normalized name: Influenza vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will be individually randomized 1:1 to receive either QIV-HD or QIV-SD, one dose, the day of the inclusion in the trial
Study: NCT05052541
Drug: THC/CBD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral solution containing 5mg THC and 50 mg CBD per 1 ml
Study: NCT05052541
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral solution containing no active drug
Study: NCT04526119
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A white film-coated tablet not containing 100 mg Z-338 Administered orally, one tablet a time and three times a day before meals for 28 days in the double-blind phase
Study: NCT06082869
Drug: Protegera™ toothpaste (NaF)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plaque Reduction
Study: NCT06082869
Drug: Crest™ Cavity Protection toothpaste (NaF)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plaque Reduction
Study: NCT06528210
Drug: Gonadotropin Releasing Hormone Agonists and Antagonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO, IM, Sub-Q injection or Sub-Q implant
Study: NCT06121492
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: In the placebo group, BCAA will be replaced with maltodextrin. Each sachet of the placebo will contain a total of 5.93 g of protein, 35.87 g of carbohydrates, 6.00 g of fat, providing 221.2 kcal of energy. Like the BCAA sachets, each placebo sachet will weigh 52 g and should be mixed with 150 ml of water. Participants in the placebo group will consume 2 sachets daily, one after breakfast and one after dinner.